Raymond James reissued their hold rating on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note issued to investors on Wednesday morning.

A number of other analysts have also weighed in on the stock. William Blair reissued a buy rating on shares of Audentes Therapeutics in a research report on Friday, October 5th. BidaskClub raised shares of Audentes Therapeutics from a hold rating to a buy rating in a research report on Tuesday, September 18th. Guggenheim assumed coverage on shares of Audentes Therapeutics in a research report on Tuesday, October 9th. They issued a neutral rating on the stock. Cowen assumed coverage on shares of Audentes Therapeutics in a research report on Friday, September 7th. They issued a sell rating and a $20.00 price objective on the stock. Finally, Mizuho reissued a buy rating and issued a $45.00 price objective on shares of Audentes Therapeutics in a research report on Wednesday, August 22nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of $36.00.

Shares of NASDAQ BOLD traded down $0.93 during mid-day trading on Wednesday, hitting $24.00. 570,381 shares of the company’s stock traded hands, compared to its average volume of 870,226. The stock has a market capitalization of $904.48 million, a price-to-earnings ratio of -7.06 and a beta of 1.99. Audentes Therapeutics has a 1 year low of $19.62 and a 1 year high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.09). During the same quarter in the previous year, the firm posted ($0.88) EPS. On average, equities analysts forecast that Audentes Therapeutics will post -3.39 EPS for the current fiscal year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 33,000 shares of the company’s stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $37.38, for a total value of $1,233,540.00. Following the transaction, the director now directly owns 365,999 shares in the company, valued at approximately $13,681,042.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $36.88, for a total transaction of $368,800.00. Following the completion of the transaction, the vice president now owns 100 shares in the company, valued at $3,688. The disclosure for this sale can be found here. Insiders sold a total of 77,039 shares of company stock worth $2,925,260 over the last three months. 6.60% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Partner Investment Management L.P. bought a new position in Audentes Therapeutics in the 2nd quarter worth about $162,000. Dynamic Technology Lab Private Ltd bought a new position in Audentes Therapeutics in the 2nd quarter worth about $226,000. Quantitative Systematic Strategies LLC bought a new position in Audentes Therapeutics in the 2nd quarter worth about $231,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Audentes Therapeutics in the 2nd quarter worth about $232,000. Finally, Cubist Systematic Strategies LLC bought a new position in Audentes Therapeutics in the 1st quarter worth about $204,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: What is Cost of Debt?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.